Veracyte announced new data demonstrating that its next-generation Percepta® Genomic Sequencing Classifier (GSC) can provide improved lung cancer diagnosis. This test is the third clinical classifier to be developed on the company's novel RNA whole-transcriptome sequencing and machine learning platform. In fact, all of the company's patent documents in the AI Biotech/Diagnostics sector relate to molecular profiling. Veracyte will also present clinical utility data demonstrating that its Envisia™ Genomic Classifier improves diagnosis of idiopathic pulmonary fibrosis, which the company has a patent for as well.
